To access AIS Channel content, please allow all cookies. Please click here to configure your preferences.
IFSO 2018 in Dubai brought together world leaders in metabolic and bariatric surgery. More than 1200 abstracts from more than 90 countries were presented. Several communications on obesity and metabolic surgery were given, focusing on the different techniques and the best indications for each of them.
Type 2 Diabetes Mellitus control, postoperative complications reduction and comparison of weight loss in different procedures were some of the main topics discussed during the congress.
This webinar summarises the highlights of the 23rd IFSO World Congress in Dubai. Asim Shabbir, Ali AMiniam, Ahmad Bashir, Alex Escalona and Bart van Wagensveld present and discuss about 30 of the best abstracts.
They also present 9 Randomized Clinical Trials, 10 Registry studies, 3 Matched case control studies, 4 Non matched controlled studies, and 3 other studies.
In the first abstract, R. Gadiot found that after a 1-year follow-up, there was no significant difference in weight loss between the Very long Roux limb -RYGB and the standard limb -RYGB groupds. There were no differences regarding deficiencies either. Similar results were found in other abstracts in 2016.
The experts agree that with longer follow-ups, the differences between the two groups should be significant in terms of weight loss and nutritional deficiencies.
The study by Ruiz de Gordezuela compares SADI-S vs Duodenal Switch. In this comparison there were no significant differences, except as regards surgical time. However, the Duodenal Switch shows better weight loss results after 3 years (BMI reduction of 46.95% vs 36.61%).
J.Ruiz-Tovar’s group showed the Impact of implementation of ERAS on Large Roux in Y Gastric Bypass (LRYGB). It associates lower postoperative pain, lower incidence of postoperative nausea and vomiting, and earlier hospital discharge.
Another group shows that weight loss 3 months after the primary bariatric surgery is predictive for weight loss up to 60 months, giving us the opportunity to select low responder patients.
In this video you will see the entire discussion on these abstracts and the opinion of the experts in the 23rd IFSO World Congress.